- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.03. | Indaptus Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.02. | Indaptus Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| INDAPTUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.02. | Indaptus Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.01. | Indaptus Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Drei Aufsichtsratsmitglieder von Indaptus Therapeutics kündigen Rücktritt an | 2 | Investing.com Deutsch | ||
| 02.01. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | Indaptus Therapeutics signs $6M securities purchase agreement with David Lazar | 1 | Seeking Alpha | ||
| 29.12.25 | Indaptus Therapeutics Enters $6 Million Securities Deal, Appoints David Lazar Co-CEO And Chairman | - | RTTNews | ||
| 29.12.25 | Indaptus Therapeutics secures $6 million investment, names new chairman | 1 | Investing.com | ||
| 29.12.25 | Indaptus Therapeutics: Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar | 2 | GlobeNewswire (USA) | ||
| 23.12.25 | Indaptus Therapeutics, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 17.11.25 | Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit | 1 | GlobeNewswire (USA) | ||
| 12.11.25 | Indaptus Therapeutics GAAP EPS of -$2.98 | 1 | Seeking Alpha | ||
| 12.11.25 | Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 169 | GlobeNewswire (Europe) | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen | |
| 12.11.25 | Indaptus Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.09.25 | Indaptus Therapeutics Provides Clinical Update | 219 | GlobeNewswire (Europe) | Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with... ► Artikel lesen | |
| 13.08.25 | Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 244 | GlobeNewswire (Europe) | NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen | |
| 25.06.25 | Indaptus Therapeutics Announces Reverse Stock Split | 208 | GlobeNewswire (Europe) | NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen | |
| 14.05.25 | Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 180 | GlobeNewswire (Europe) | NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 74,25 | -0,07 % | JETZT über 50 % KURSPOTENZIAL!? BioNTech, TUI und Bayer-Partner MustGrow | Lust auf ein Investment in einen Geheimtipp mit riesigem Marktpotenzial? Dann ist die Aktie von MustGrow interessant. Das Unternehmen wird mit unter 40 Mio. CAD bewertet. Die biologischen und regenerativen... ► Artikel lesen | |
| BB BIOTECH | 46,400 | -0,22 % | Dividendenbekanntmachungen (23.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,94 CHF 1,0309 EUR AECON GROUP INC CA00762V1094 0,1925 CAD 0,1212 EUR AMPHENOL CORPORATION US0320951017 0... ► Artikel lesen | |
| QIAGEN | 34,540 | +1,75 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 41,725 | -0,78 % | Moderna vor entscheidender Bewährungsprobe | Moderna steht derzeit wieder stärker im Fokus technischer Beobachter. Im Chartbild zeigen sich Hinweise auf eine Stabilisierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| AMGEN | 303,90 | -0,23 % | Amgen: Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis | Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention
VESALIUS-CV Subgroup Findings Reinforce Benefit... ► Artikel lesen | |
| NOVAVAX | 6,967 | -1,26 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| STRYKER | 284,10 | -0,18 % | Stryker, Zimmer Biomet & mehr Dividenden im global market - Ex-Tag 31.03.2026 | ||
| ILLUMINA | 105,68 | +0,27 % | Argus hebt Illumina-Kursziel wegen neuer Produkte auf 145 US-Dollar an | ||
| CRISPR THERAPEUTICS | 39,000 | +1,04 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| AAP IMPLANTATE | 1,360 | -0,73 % | AAP Implantate AG - Schwächer, aber nicht richtungslos | ||
| OCUGEN | 1,543 | +0,75 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,276 | +3,76 % | Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks | ||
| MAINZ BIOMED | 0,416 | -1,54 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| NOVONESIS | 51,94 | +0,04 % | Novonesis (Novozymes A/S): Resolutions from the Annual General Meeting 2026 | Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,225 | +0,49 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen |
INDAPTUS THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INDAPTUS THERAPEUTICS INC finden Sie auf Wallstreet Online.